RETAIN is a Phase II study that enrolls patients with MIBC to undergo surgery or a bladder-preserving approach according to the mutational profile of the tumor (including ATM, RB1, FANCC and ERCC2 mutations) (NCT02710734) [72]. The gene discussed is ATM; the disease is neoplasm.